ES2006109A6 - Un procedimiento para preparar un conjugado de inmunoglobulina. - Google Patents

Un procedimiento para preparar un conjugado de inmunoglobulina.

Info

Publication number: ES2006109A6
Authority: ES; Spain
Prior art keywords: preparing; procedure; immunoglobulin conjugate; antigen; immunoglobulin
Prior art date: 1987-03-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

ES8800719A

Other languages

English (en)

Spanish (es)

Inventor

Ian Farquhar Mckenzie

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Italia SRL

Original Assignee

Farmitalia Carlo Erba SRL

Carlo Erba SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-03-11

Filing date

1988-03-10

Publication date

1989-04-01

1988-03-10 Application filed by Farmitalia Carlo Erba SRL, Carlo Erba SpA filed Critical Farmitalia Carlo Erba SRL

1989-04-01 Publication of ES2006109A6 publication Critical patent/ES2006109A6/es

Status Expired legal-status Critical Current

Links

108060003951 Immunoglobulin Proteins 0.000 title abstract 2
102000018358 immunoglobulin Human genes 0.000 title abstract 2
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000000779 depleting effect Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
229960000908 idarubicin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES8800719A 1987-03-11 1988-03-10 Un procedimiento para preparar un conjugado de inmunoglobulina. Expired ES2006109A6 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPI080387		1987-03-11
AUPI295587		1987-07-07

Publications (1)

Publication Number	Publication Date
ES2006109A6 true ES2006109A6 (es)	1989-04-01

Family

ID=25643244

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES8800719A Expired ES2006109A6 (es)	1987-03-11	1988-03-10	Un procedimiento para preparar un conjugado de inmunoglobulina.

Country Status (29)

Country	Link
US (1)	US5798097A (de)
JP (1)	JP2736255B2 (de)
KR (1)	KR0130906B1 (de)
CN (1)	CN1045621C (de)
AT (1)	AT395375B (de)
AU (1)	AU622105B2 (de)
BE (1)	BE1001051A4 (de)
CA (1)	CA1329156C (de)
CH (1)	CH678815A5 (de)
CZ (1)	CZ161288A3 (de)
DE (1)	DE3808166C2 (de)
DK (1)	DK173792B1 (de)
ES (1)	ES2006109A6 (de)
FI (1)	FI98706C (de)
FR (1)	FR2612074B1 (de)
GB (1)	GB2203154B (de)
GR (1)	GR1000059B (de)
HU (1)	HU205266B (de)
IE (1)	IE64781B1 (de)
IL (1)	IL85688A0 (de)
IT (1)	IT8819746A0 (de)
MY (1)	MY103231A (de)
NL (1)	NL8800610A (de)
NO (1)	NO178954C (de)
NZ (1)	NZ223834A (de)
PT (1)	PT86960B (de)
RU (1)	RU2106147C1 (de)
SE (1)	SE503402C2 (de)
YU (1)	YU46858B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6824777B1 (en)	1992-10-09	2004-11-30	Licentia Ltd.	Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
WO2002060950A2 (en)	1994-11-14	2002-08-08	Ludwig Institute For Cancer Research	Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
CA2345276C (en) *	1998-10-09	2011-03-29	Ludwig Institute For Cancer Research	Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
EP1343531A2 (de) *	2000-12-21	2003-09-17	McGILL UNIVERSITY	Konjugate von antikörpern und antikrebsmitteln
EP1620564A4 (de) *	2003-04-18	2008-03-12	Cytovia Inc	Verfahren zur behandlung von auf apoptoseinduktion reagierenden krankheiten und screening-tests
GB0511266D0 (en) *	2005-06-02	2005-07-13	Trust	Chemical compounds
US20080108138A1 (en) *	2006-06-13	2008-05-08	Vermette Patrick	Bioactive compositions and their use in cell patterning
CN110251668A (zh)	2010-11-30	2019-09-20	霍夫曼-拉罗奇有限公司	低亲和力血脑屏障受体抗体及其用途
SMT202000088T1 (it)	2013-02-18	2020-03-13	Vegenics Pty Ltd	Molecole leganti ligandi e relativi usi
EP4157241A4 (de) *	2020-05-29	2025-01-08	The Regents of the University of California	Mittel und verfahren zur behandlung von tauopathien

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1500421A (en) *	1975-01-22	1978-02-08	Farmaceutici Italia	Optically active anthracyclinones
AT343812B (de) *	1975-01-22	1978-06-26	Farmaceutici Italia	Verfahren zur herstellung von neuen optisch aktiven daunosaminylderivaten von anthracyclinonen
AT346838B (de) *	1975-01-22	1978-11-27	Farmaceutici Italia	Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
AT343811B (de) *	1975-01-22	1978-06-26	Farmaceutici Italia	Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
GB1511680A (en)	1975-11-18	1978-05-24	Farmaceutici Italia	Daunosaminyl anthracyclinones
GB1541436A (en) *	1976-02-02	1979-02-28	Searle & Co	Immunological materials
US4950738A (en) *	1984-09-13	1990-08-21	Cytogen Corporation	Amine derivatives of anthracycline antibiotics
US5162512A (en) *	1982-03-09	1992-11-10	Cytogen Corporation	Amine derivatives of anthracycline antibodies
US4867973A (en) *	1984-08-31	1989-09-19	Cytogen Corporation	Antibody-therapeutic agent conjugates
JPS59186924A (ja) *	1983-04-08	1984-10-23	Kureha Chem Ind Co Ltd	ヒト免疫グロブリン結合抗腫瘍剤
US4545985A (en) *	1984-01-26	1985-10-08	The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services	Pseudomonas exotoxin conjugate immunotoxins
GB8413464D0 (en) *	1984-05-25	1984-07-04	Erba Farmitalia	Anthracycline-anionic polymer conjugates
JPS61155334A (ja) *	1984-12-28	1986-07-15	Teijin Ltd	殺細胞性修飾免疫グロブリン及びその製造方法
FR2584293B1 (fr) *	1985-07-04	1989-03-17	Ire Celltarg Sa	Anticorps utiles comme agents de pilotage et conjugues les incorporant

1988
- 1988-03-10 JP JP63055074A patent/JP2736255B2/ja not_active Expired - Lifetime
- 1988-03-10 IE IE70188A patent/IE64781B1/xx not_active IP Right Cessation
- 1988-03-10 KR KR1019880002464A patent/KR0130906B1/ko not_active Expired - Fee Related
- 1988-03-10 BE BE8800268A patent/BE1001051A4/fr not_active IP Right Cessation
- 1988-03-10 AU AU12881/88A patent/AU622105B2/en not_active Expired
- 1988-03-10 ES ES8800719A patent/ES2006109A6/es not_active Expired
- 1988-03-10 IL IL85688A patent/IL85688A0/xx not_active IP Right Cessation
- 1988-03-10 MY MYPI88000250A patent/MY103231A/en unknown
- 1988-03-10 YU YU48288A patent/YU46858B/sh unknown
- 1988-03-10 HU HU881160A patent/HU205266B/hu unknown
- 1988-03-10 CA CA000561042A patent/CA1329156C/en not_active Expired - Lifetime
- 1988-03-10 NZ NZ223834A patent/NZ223834A/xx unknown
- 1988-03-11 GB GB8805865A patent/GB2203154B/en not_active Expired - Lifetime
- 1988-03-11 FR FR888803233A patent/FR2612074B1/fr not_active Expired - Lifetime
- 1988-03-11 CH CH936/88A patent/CH678815A5/de not_active IP Right Cessation
- 1988-03-11 FI FI881158A patent/FI98706C/fi not_active IP Right Cessation
- 1988-03-11 DE DE3808166A patent/DE3808166C2/de not_active Expired - Lifetime
- 1988-03-11 GR GR880100148A patent/GR1000059B/el not_active IP Right Cessation
- 1988-03-11 SE SE8800886A patent/SE503402C2/sv not_active IP Right Cessation
- 1988-03-11 AT AT0067488A patent/AT395375B/de not_active IP Right Cessation
- 1988-03-11 CN CN88101810A patent/CN1045621C/zh not_active Expired - Lifetime
- 1988-03-11 NO NO881105A patent/NO178954C/no not_active IP Right Cessation
- 1988-03-11 PT PT86960A patent/PT86960B/pt not_active IP Right Cessation
- 1988-03-11 IT IT8819746A patent/IT8819746A0/it unknown
- 1988-03-11 NL NL8800610A patent/NL8800610A/nl not_active IP Right Cessation
- 1988-03-11 CZ CS881612A patent/CZ161288A3/cs not_active IP Right Cessation
- 1988-03-11 DK DK198801315A patent/DK173792B1/da not_active IP Right Cessation
1992
- 1992-06-15 RU SU5052164A patent/RU2106147C1/ru active
1995
- 1995-04-11 US US08/420,712 patent/US5798097A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2736255B2 (ja)	1998-04-02
IE880701L (en)	1988-09-11
SE503402C2 (sv)	1996-06-10
DE3808166C2 (de)	1997-08-28
AU622105B2 (en)	1992-04-02
NL8800610A (nl)	1988-10-03
US5798097A (en)	1998-08-25
NZ223834A (en)	1990-05-28
IL85688A0 (en)	1988-08-31
HU205266B (en)	1992-04-28
PT86960A (pt)	1988-04-01
NO881105D0 (no)	1988-03-11
FI98706C (fi)	1997-08-11
CA1329156C (en)	1994-05-03
FR2612074A1 (fr)	1988-09-16
NL195078C (de)	2003-07-30
GR1000059B (el)	1990-06-27
CN1045621C (zh)	1999-10-13
IE64781B1 (en)	1995-09-06
BE1001051A4 (fr)	1989-06-20
GR880100148A (en)	1989-01-31
RU2106147C1 (ru)	1998-03-10
KR0130906B1 (ko)	1998-04-23
JPS63301832A (ja)	1988-12-08
NO178954B (no)	1996-04-01
DK131588D0 (da)	1988-03-11
GB2203154B (en)	1991-06-26
CH678815A5 (de)	1991-11-15
MY103231A (en)	1993-05-29
YU48288A (en)	1989-08-31
NO178954C (no)	1996-07-10
FR2612074B1 (fr)	1991-06-21
SE8800886D0 (sv)	1988-03-11
FI881158L (fi)	1988-09-12
IT8819746A0 (it)	1988-03-11
GB8805865D0 (en)	1988-04-13
CN88101810A (zh)	1988-11-09
AU1288188A (en)	1988-09-15
FI881158A0 (fi)	1988-03-11
AT395375B (de)	1992-12-10
YU46858B (sh)	1994-06-24
DE3808166A1 (de)	1988-09-22
DK173792B1 (da)	2001-11-05
PT86960B (pt)	1992-06-30
GB2203154A (en)	1988-10-12
CZ281193B6 (cs)	1996-07-17
KR880010775A (ko)	1988-10-24
HUT46547A (en)	1988-11-28
FI98706B (fi)	1997-04-30
CZ161288A3 (en)	1996-07-17
NO881105L (no)	1988-09-12
DK131588A (da)	1988-09-12
ATA67488A (de)	1992-05-15
SE8800886L (sv)	1989-09-12

Legal Events

Date	Code	Title	Description
1997-06-16	PC1A	Transfer granted
2003-08-01	PC1A	Transfer granted
2008-10-16	FD1A	Patent lapsed	Effective date: 20080311

Publication	Publication Date	Title
MY104946A (en)	1994-07-30	Antigen antibody conjugate.
GB9009548D0 (en)	1990-06-20	Chimeric antibody and method
DE69221147D1 (de)	1997-09-04	Nicht glycosylierter Anti-CD3-IgG-Antikörper
ATE171461T1 (de)	1998-10-15	Immunstimulierende monoklonale antikörper
PT743856E (pt)	2003-12-31	Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros
ES8506091A1 (es)	1985-06-16	Un procedimiento para obtener un polidoma
FI864037A0 (fi)	1986-10-06	Monoklonala antikroppar mot broestkraefta hos maenniska.
FI913891A7 (fi)	1991-08-16	Uusi monoklonaalinen vasta-aine uutta antigeenia vastaan, joka liittyy ihmisen kasvaimiin
CA2078118A1 (en)	1991-10-26	Cc-1065 analogs
ES8405071A1 (es)	1984-05-16	Un procedimiento de preparacion de conjugados inmunoenzimaticos.
IL89823A0 (en)	1989-12-15	Antibody hetero conjugates and pharmaceutical compositions containing them
ES531081A0 (es)	1985-07-16	Un procedimiento para la produccion de un conjugado
ES2116789T3 (es)	1998-07-16	Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y empleo.
ES2006109A6 (es)	1989-04-01	Un procedimiento para preparar un conjugado de inmunoglobulina.
EP0683822A4 (de)	1997-11-05	Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung.
EP0352722A3 (de)	1991-07-17	Bindungstests für Adenocarcinoma-Antigen und Reagenzien
PT733903E (pt)	2002-06-28	Processo de dosagem imunologica de cortisol nomeadamente urinario e reagentes utilizados
IN172885B (de)	1993-12-25
WO1987007302A3 (en)	1988-01-14	MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES
NZ314010A (en)	2000-09-29	A method of targeting intracellular binding proteins using a lipidized antibody
ATE14937T1 (de)	1985-08-15	Monoklonaler hybridoma-antikoerper spezifisch fuer karzinoembryonisches antigen mit hohem molekulargewicht.